VANCOUVER, BC and MENLO PARK, CA--(Marketwired - August 22, 2013) - DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to announce the appointment of Mr. Robert J. Toth, Jr. to the company's Board of Directors.
Mr. Toth is a seasoned executive and active biotechnology investor with more than sixteen years of experience in both the financial and biotechnology industries. His background is a unique blend of operational experience acquired by working within the biotechnology community combined with a high profile Wall Street career. From 2004-2005, Mr. Toth served as a consulting analyst to Narragansett Asset Management, a New York-based healthcare-focused hedge fund, where he advised the firm on biotechnology investments. From 2001-2003, he was the Senior Portfolio Manager for San Francisco-based EGM Capital's Medical Technology hedge fund, where he was responsible for managing and maintaining a dedicated medical technology portfolio. Mr. Toth began his Wall Street career in 1996 as an Equity Research Associate for Vector Securities International, a healthcare-focused brokerage firm. From 1997-1999 he served as Senior Biotechnology Analyst. He joined Prudential Securities as Senior Vice President and Biotechnology Analyst where he served from 1999-2001 following Prudential's acquisition of Vector. His responsibilities included the analysis of commercial, clinical and scientific fundamentals of oncology- and genomics-based biotechnology companies on behalf of institutional investors. Mr. Toth was named to the Wall Street Journal's All-Star List for stock picking in 1999.
Mr. Toth's operational experience was acquired by working extensively within the biotechnology sector. From 1993-1996 he held both business development and research positions at Connectics Corporation. He assisted with intellectual property assessment and technology out-licensing while working at the University of Washington's Office of Technology Transfer (1992-93). He served in a broad range of manufacturing, research, and clinical capacities while working at Genentech, Inc. (1987-91). Mr. Toth holds an MBA from the University of Washington and dual Bachelor of Science degrees in Biological Sciences and Biochemistry from California Polytechnic State University, San Luis Obispo.
"We are very pleased to have Rob join our Board of Directors," said Jeffrey Bacha, president & CEO of DelMar. "His extensive experience on both the operating and financial sides of our industry will be an asset as we build our company and seek to realize our goal of developing and commercializing new cancer therapies."
About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, email@example.com